3lfn
From Proteopedia
(Difference between revisions)
												
			
			| Line 1: | Line 1: | ||
==Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitor==  | ==Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitor==  | ||
| - | <StructureSection load='3lfn' size='340' side='right' caption='[[3lfn]], [[Resolution|resolution]] 2.28Å' scene=''>  | + | <StructureSection load='3lfn' size='340' side='right'caption='[[3lfn]], [[Resolution|resolution]] 2.28Å' scene=''>  | 
== Structural highlights ==  | == Structural highlights ==  | ||
| - | <table><tr><td colspan='2'>[[3lfn]] is a 1 chain structure with sequence from [  | + | <table><tr><td colspan='2'>[[3lfn]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3LFN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3LFN FirstGlance]. <br>  | 
| - | </td></tr><tr id='  | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.28Å</td></tr>  | 
| - | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A27:N-[6-(4-HYDROXYPHENYL)-5-PHENYL-1H-INDAZOL-3-YL]BUTANAMIDE'>A27</scene></td></tr>  | |
| - | <tr id='  | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3lfn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3lfn OCA], [https://pdbe.org/3lfn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3lfn RCSB], [https://www.ebi.ac.uk/pdbsum/3lfn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3lfn ProSAT]</span></td></tr>  | 
| - | + | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[  | + | |
</table>  | </table>  | ||
== Function ==  | == Function ==  | ||
| - | [  | + | [https://www.uniprot.org/uniprot/CDK2_HUMAN CDK2_HUMAN] Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization.<ref>PMID:10499802</ref> <ref>PMID:11051553</ref> <ref>PMID:10995386</ref> <ref>PMID:10995387</ref> <ref>PMID:10884347</ref> <ref>PMID:11113184</ref> <ref>PMID:15800615</ref> <ref>PMID:18372919</ref> <ref>PMID:20147522</ref> <ref>PMID:20079829</ref> <ref>PMID:20935635</ref> <ref>PMID:20195506</ref> <ref>PMID:19966300</ref> <ref>PMID:21262353</ref> <ref>PMID:21596315</ref> <ref>PMID:21319273</ref> <ref>PMID:17495531</ref>   | 
== Evolutionary Conservation ==  | == Evolutionary Conservation ==  | ||
[[Image:Consurf_key_small.gif|200px|right]]  | [[Image:Consurf_key_small.gif|200px|right]]  | ||
| Line 22: | Line 20: | ||
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=3lfn ConSurf].  | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=3lfn ConSurf].  | ||
<div style="clear:both"></div>  | <div style="clear:both"></div>  | ||
| - | <div style="background-color:#fffaf0;">  | ||
| - | == Publication Abstract from PubMed ==  | ||
| - | From an HTS hit, a series of potent and selective inhibitors of GSK3beta have been designed based on a Cdk2-homology model and with the help of several crystal structures of the compounds within Cdk2.  | ||
| - | |||
| - | Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.,Lesuisse D, Dutruc-Rosset G, Tiraboschi G, Dreyer MK, Maignan S, Chevalier A, Halley F, Bertrand P, Burgevin MC, Quarteronet D, Rooney T Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. Epub 2010 Jan 25. PMID:20167481<ref>PMID:20167481</ref>  | ||
| - | |||
| - | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>  | ||
| - | </div>  | ||
| - | <div class="pdbe-citations 3lfn" style="background-color:#fffaf0;"></div>  | ||
==See Also==  | ==See Also==  | ||
| - | *[[Cyclin-dependent kinase|Cyclin-dependent kinase]]  | + | *[[Cyclin-dependent kinase 3D structures|Cyclin-dependent kinase 3D structures]]  | 
== References ==  | == References ==  | ||
<references/>  | <references/>  | ||
__TOC__  | __TOC__  | ||
</StructureSection>  | </StructureSection>  | ||
| - | [[Category:   | + | [[Category: Homo sapiens]]  | 
| - | [[Category:   | + | [[Category: Large Structures]]  | 
| - | [[Category: Dreyer  | + | [[Category: Dreyer MK]]  | 
| - | [[Category: Loenze  | + | [[Category: Loenze P]]  | 
| - | [[Category: Schimanski-Breves  | + | [[Category: Schimanski-Breves S]]  | 
| - | [[Category: Wendt  | + | [[Category: Wendt KU]]  | 
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitor
  | |||||||||||

